BioWorld

Aug. 8, 2008

Ahead of OncoGenex Merger, Sonus Adds Caspase Program

Compliance in Off-Label and Journal Articles

Other News To Note

Clinic Roundup

Appointments And Advancements

Celgene Calls it Quits in GPC Satraplatin Deal

Celgene Corp. has ended its nearly three-year partnership with embattled German firm GPC Biotech AG on its prostate cancer drug satraplatin. (BioWorld Today) Read More

Acorda's $114M Offering to Support NDA, Launch

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...